Latest news with #LaurusLabsLtd
Business Standard
28-07-2025
- Business
- Business Standard
Sudarshan Chemical Industries Ltd leads gainers in 'A' group
Sterlite Technologies Ltd, Cartrade Tech Ltd, Laurus Labs Ltd and Advanced Enzyme Technologies Ltd are among the other gainers in the BSE's 'A' group today, 28 July 2025. Sterlite Technologies Ltd, Cartrade Tech Ltd, Laurus Labs Ltd and Advanced Enzyme Technologies Ltd are among the other gainers in the BSE's 'A' group today, 28 July 2025. Sudarshan Chemical Industries Ltd surged 10.77% to Rs 1384.2 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 41760 shares were traded on the counter so far as against the average daily volumes of 4871 shares in the past one month. Sterlite Technologies Ltd soared 6.71% to Rs 124.85. The stock was the second biggest gainer in 'A' group. On the BSE, 8.5 lakh shares were traded on the counter so far as against the average daily volumes of 6.33 lakh shares in the past one month. Cartrade Tech Ltd spiked 6.41% to Rs 2019.35. The stock was the third biggest gainer in 'A' group. On the BSE, 63622 shares were traded on the counter so far as against the average daily volumes of 16544 shares in the past one month. Laurus Labs Ltd spurt 6.35% to Rs 891.25. The stock was the fourth biggest gainer in 'A' group. On the BSE, 6.59 lakh shares were traded on the counter so far as against the average daily volumes of 1.02 lakh shares in the past one month. Advanced Enzyme Technologies Ltd advanced 5.71% to Rs 345. The stock was the fifth biggest gainer in 'A' group. On the BSE, 72160 shares were traded on the counter so far as against the average daily volumes of 15281 shares in the past one month.
Business Upturn
28-07-2025
- Business
- Business Upturn
Why are Laurus Labs shares up over 2% today? Explained
By Aditya Bhagchandani Published on July 28, 2025, 09:27 IST Shares of Laurus Labs Ltd surged over 2% to ₹856.25 in early trade on Monday, making it one of the top gainers on the NSE. The sharp upmove comes on the back of a stellar Q1 performance, a major land allotment for expansion, and bullish commentary from top brokerages. Here's what's driving the stock higher: 1. Blockbuster Q1 FY26 Results Laurus Labs posted a net profit of ₹163 crore, up a massive 1,185% YoY from ₹13 crore a year ago. Revenue : ₹1,570 crore (up 31% YoY) : ₹1,570 crore (up 31% YoY) EBITDA : ₹389 crore (up 127% YoY) : ₹389 crore (up 127% YoY) EBITDA Margin: Expanded significantly YoY, reflecting strong operating leverage This marked the company's third consecutive earnings beat, with particularly robust performance in the CDMO (Contract Development and Manufacturing Organization) and ARV (antiretroviral) verticals. 2. Strategic Land Allotment for Laurus Pharma Zone The Andhra Pradesh government allotted 531.77 acres to Laurus in IP Rambilli Phase-II (Anakapalli District) for the development of a Laurus Pharma Zone (LPZ). Planned investment : ₹5,630 crore : ₹5,630 crore Job creation target : 6,350 people : 6,350 people Phased execution over 8 years This land is crucial for Laurus' long-term growth strategy, giving it the physical base to scale up manufacturing capabilities across API, formulations, and novel therapies. 3. Bullish Broker Commentary Motilal Oswal (MOSL) has maintained a 'Buy' rating, raising the target price to ₹970 (from ₹860) Upgraded gross margin guidance to 55–60% (from 50–55%) Strong CDMO visibility and pipeline Raised earnings estimates by 16% for FY26 and 7% for FY27 has maintained a rating, raising the (from ₹860) Antique Stock Broking gave a more balanced view, maintaining a 'Hold' but still raising the target to ₹700 (from ₹520), citing: Limited visibility in CDMO contracts ARV outlook steady but not exceptional Scale-up challenges in Bio CDMO segment gave a more balanced view, but still raising the target to ₹700 (from ₹520), citing: Still, the firm expects ~16% revenue CAGR from FY25 to FY28, and EBITDA margins to rise from 19% to 30% over the same period. Segmental Strength & Capex Plans The CDMO business is growing rapidly , now contributing more meaningfully to revenues , now contributing more meaningfully to revenues The company is also building a new Gene/ADC facility in Hyderabad and a microbial fermentation plant in Vizag and a Plans to invest ₹5,000 crore over the next 5 years, with net debt/EBITDA expected to stay in the 2.2x–2.5x range Market Snapshot: Stock Price : ₹856.25 (up 2.21%) : ₹856.25 (up 2.21%) 52-week range : ₹417.70 – ₹855.00 : ₹417.70 – ₹855.00 Market Cap : ₹460.32 billion : ₹460.32 billion P/E Ratio: 90.53 Laurus Labs' sharp rally today is driven by optimism around its blockbuster Q1 numbers, the government-backed land allotment, and analyst upgrades, all of which point to a long runway for growth. While near-term execution challenges remain, the market appears to be betting on Laurus' transformational expansion strategy and strong positioning in high-value pharma segments. Disclaimer: This article is for informational purposes only and should not be construed as investment advice. Please consult your financial advisor before making any investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Mint
07-07-2025
- Business
- Mint
Stock market today: Trade setup for Nifty 50 to global markets; Eight stocks to buy or sell Monday—7 July 2025
Stock Market Today: Amid concerns around trade negotiations in the US, the markets continued to consolidate during the week ended 4 July 2025. The Benchmark Nifty 50 index ended around 0.7% lower at 25,461.00. Bank Nifty also followed suit, ending 0.75% lower at 57,031.90, while Realty was another loser, though IT and Healthcare were among key gainers. In the broader markets, the mid-cap and small-cap indices gained 0.3% to 0.5%. For the Nifty, 25,500 would act as an immediate resistance zone, above which it could move up to 25,670 and the 25,800–25,900 cone. On the flip side, if the market falls below 25,300, it could slip to 25,000–24,950, said Amol Athawale, VP-Technical Research, Kotak Securities. For Bank Nifty, the 20-day SMA (Simple Moving Average) at 56,500 is a key level to watch, added Athawale. The coming week holds significant importance not only for Indian markets but for global equities as well. The most anticipated event is the outcome of the U.S. trade deadline on July 9, which could shape global trade dynamics. Investors will also closely monitor the release of the U.S. Federal Reserve's FOMC minutes on the same day, as per Ajit Mishra—SVP, Research, Religare Broking Ltd. Domestically, the spotlight will shift to corporate earnings, with IT major TCS and retail giant Avenue Supermarts among the prominent companies scheduled to report their quarterly results, setting the tone for the Q1 earnings season. Regarding stocks to buy today, market experts—Sumeet Bagadia, Executive Director at Choice Broking; Ganesh Dongre, Senior Manager of Technical Research at Anand Rathi; and Shiju Koothupalakkal, Senior Manager of Technical Research at Prabhudas Lilladher—recommended these eight intraday stocks for today: V2 Retail Ltd, Laurus Labs Ltd, Indian Oil Corporation Ltd, Punjab National Bank, Punjab National Bank, Ideaforge Technology Ltd, VA Tech Wabag Ltd, and Fusion Finance Ltd. 1. V2 Retail Ltd—Bagadia recommends buying V2RETAIL at around ₹ 1923.9, keeping the stop loss at ₹ 1850 keeping the target price of ₹ 2077 V2RETAIL, currently trading at 1923.9, exhibits a strong uptrend, supported by its consistent position above key exponential moving averages (EMAs). After a prolonged range-bound phase over the past two months, the stock appears to have resumed its upward journey. With higher lows being formed on the daily chart, the medium-term uptrend remains intact. 2. Laurus Labs Ltd—Bagadia recommends buying LAURUSLABS at around ₹ 776, keeping stop loss at ₹ 748, and keeping target price at ₹ 838 Laurus Labs is currently trading at ₹ 776 and continues to exhibit strong bullish momentum, forming a consistent pattern of higher highs and higher lows. The stock recently marked a fresh 52-week high at ₹ 777 and is now approaching a key resistance zone near ₹ 800. A breakout above this level could trigger renewed buying interest and further fuel upward momentum 3. Indian Oil Corporation Ltd—Dongre recommends buying Indian Oil Corporation, or IOC, at around ₹ 152, keeping Stoploss at ₹ 145 for a target price of 158 Stock has exhibited a strong, notable, continued bullish pattern, offering another promising opportunity for short-term traders. The stock is currently priced at ₹ 152 and maintaining strong support at ₹ 145. The technical setup indicates the potential for a price retracement towards the ₹ 158 level. With the stock reversing from a support base and showing signs of renewed strength, entering at the current market price with a stop-loss at ₹ 145 offers a prudent approach to capturing the anticipated upside. 4. Multi Commodity Exchange of India Ltd—Dongre recommends buying MCX at ₹ 8865, with a stop loss ₹ 8500, for a target price ₹ 9200 Stock has exhibited a strong, notable, continued bullish pattern, offering another promising opportunity for short-term traders. The stock is currently priced at ₹ 8865 and maintaining strong support at ₹ 8500. The technical setup indicates the potential for a price retracement towards the ₹ 9200 level. With the stock reversing from a support base and showing signs of renewed strength, entering at the current market price with a stop-loss at ₹ 8500 offers a prudent approach to capturing the anticipated upside. 5 Punjab National Bank- Dongre recommends buying PNB at around ₹ 111, keeping Stop Loss at ₹ 107 for a target price of ₹ 118. In the recent short-term trend analysis of the stock, a notable bullish reversal pattern has emerged. This technical pattern suggests that there could be a temporary retracement in the stock's price, possibly to around Rs. 118. Currently, the stock is holding a crucial support level at Rs.107. Given this scenario, there is potential for the stock to rebound towards the Rs.118 level in the near future. 6. Ideaforge Technology Ltd.-Koothupalakkal recommends buying IDEA FORGE at around ₹ 590 for a target price of ₹ 630, keeping Stop loss at ₹ 577 The stock has witnessed a short period of correction from the ₹ 664 level and has taken support at the ₹ 570 zone, indicating an ascending channel pattern on the daily chart with improvement in the bias, anticipating a further rise in the coming sessions. The RSI has witnessed a gradual slide from the highly overbought zone and is currently well placed with strength indicated, signaling a buy having much upside potential from the current rate. With the chart looking good, we suggest buying the stock for an upside target of the ₹ 630 level, keeping the stop loss at the the ₹ 577 level. 7. VA Tech Wabag Ltd - Koothupalakkal recommends buying WABAG at around ₹ 1466 for a target price of ₹ 1550. keeping Stop loss at around ₹ 1435 The stock has witnessed a gradual slide after peaking out near the 1680 zone and has corrected quite significantly, currently indicating signs of positive development. After consolidating near the 1415 level, the stock has indicated a bullish candle on the daily chart to improve the bias and anticipate for further rise in the coming days. The RSI is well positioned, correcting from the overbought zone, and has arrived near the oversold area, indicating a positive trend reversal to signal a buy. With much upside potential visible and the chart technically looking good, we suggest buying the stock for an upside target of 1550, keeping the stop loss at the 1435 level. 8. Fusion Finance Ltd - Koothupalakkal recommends buying FUSION FINANCE at around ₹ 194.65 for a target price of ₹ 210, keeping the stop loss at ₹ 189 The stock has indicated an ascending channel pattern on the daily chart with a series of higher bottom formations, and currently, once again, taking support near the 187 zone has indicated a pullback with a positive candle formation to improve the bias and anticipate a further rise in the coming sessions. The RSI with a short period of correction has once again shown signs of improvement with improvement in the bias, and we can expect a further upward move. With decent volume participation visible and the chart technically looking attractive, we suggest buying the stock for an upside target of ₹ 210, keeping the stop loss at the ₹ 189 level. Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
26-06-2025
- Business
- Business Standard
Laurus Labs Ltd spurts 1.63%, up for five straight sessions
Laurus Labs Ltd is quoting at Rs 680.9, up 1.63% on the day as on 12:44 IST on the NSE. The stock is up 60.78% in last one year as compared to a 5.65% gain in NIFTY and a 11.34% gain in the Nifty Pharma. Laurus Labs Ltd rose for a fifth straight session today. The stock is quoting at Rs 680.9, up 1.63% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.62% on the day, quoting at 25402.2. The Sensex is at 83287.99, up 0.64%. Laurus Labs Ltd has added around 13.14% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 0.94% in last one month and is currently quoting at 21804.8, down 0.35% on the day. The volume in the stock stood at 9.15 lakh shares today, compared to the daily average of 16.82 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 678.1, up 0.97% on the day. Laurus Labs Ltd is up 60.78% in last one year as compared to a 5.65% gain in NIFTY and a 11.34% gain in the Nifty Pharma index.
Time of India
09-06-2025
- Business
- Time of India
Stock market update: Nifty Pharma index advances 0.66%
NEW DELHI: The Nifty Pharma index closed on a positive note on Monday. Shares of Laurus Labs Ltd .(up 3.95 per cent), Biocon Ltd.(up 2.46 per cent), Zydus Lifesciences Ltd.(up 1.41 per cent), Divi's Laboratories Ltd .(up 1.36 per cent) and Granules India Ltd .(up 1.26 per cent) ended the day as top gainers in the pack. On the other hand, J B Chemicals & Pharmaceuticals Ltd.(down 1.47 per cent), Lupin Ltd.(down 0.26 per cent), Dr. Reddy's Laboratories Ltd.(down 0.14 per cent), Ipca Laboratories Ltd .(down 0.12 per cent) and Aurobindo Pharma Ltd .(down 0.1 per cent) finished as the top losers of the day. The Nifty Pharma index closed 0.66 per cent up at 21826.8. Benchmark NSE Nifty50 index ended up 100.16 points at 25103.2, while the BSE Sensex stood up 256.22 points at 82445.21. Live Events Among the 50 stocks in the Nifty index, 39 ended in the green, while 11 closed in the red. Shares of Vodafone Idea , JP Power, Reliance Power , Suzlon Energy and Capri Global were among the most traded shares on the NSE. Shares of Indef Manufacturing, Hybrid Financial Services , TVS Electronics, Sudarshan Chemical and MCX India hit their fresh 52-week highs in today's trade, while Shree Ram Proteins , Varanium Cloud , Techindia Nirman , BSL Ltd and United Drilling hit their fresh 52-week lows.
